Eli Lilly's TOGETHER-PsO Open-label Phase 3B Trial Of Concomitant Use Of Taltz (Ixekizumab) And Zepbound (Tirzepatide) Compared To Taltz Alone For Moderate-to-severe Plaque Psoriasis And Obesity Met The Primary And All Key Secondary Endpoints